Connect with us

Media

Woman stuns social media with ‘revolutionary’ kitchen organization hack: ‘My jaw just dropped’ – Yahoo Canada Finance

Published

 on


GlobeNewswire

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74Broad expression of FAP demonstrated in tumors or in tumor stroma across many solid tumors1,2,3Novartis Oncology continues to reimagine cancer care through development of robust radioligand therapy portfolio Basel, March 30, 2021 — Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc. The FAP assets were originally developed at the University of Heidelberg. The agreement also includes co-exclusive rights for Novartis to develop imaging applications for these assets. Fibroblast activation protein (FAP) is a cell-surface protein expressed at low levels in most normal adult tissues, but over-expressed in common cancers, particularly on cancer-associated fibroblasts that form the tumor stroma, which is essential for growth1,2,3,4. High FAP expression on cancer-associated fibroblasts is generally associated with worse prognosis in solid tumors due to promotion of tumorigenesis and progression4,5,6,7. “We continue to invest in radioligand therapy as one of the four unique platforms of Novartis Oncology. We believe working across multiple approaches is the key to reimagining cancer care,” said Susanne Schaffert, PhD, President, Novartis Oncology. “FAP is an exciting target and these agents are a great fit with our radioligand therapy pipeline, which we are actively investigating across multiple tumor types. We believe this technology has the potential to transform many patients’ lives.” Targeted radioligand therapy is a type of precision medicine combining two key elements: a targeting compound, or ligand, and a radioactive isotope, causing DNA damage that inhibits tumor growth and replication. These targeted drugs bind to markers or proteins over-expressed by certain tumors, or tumor-associated tissue, such as stroma. Due to the high-affinity of these agents for specific tumor cells or associated tumor tissue, surrounding healthy tissue is less affected. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” “actively,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the Fibroblast Activating Protein (FAP) targeting agents, including FAPI-46 and FAPI-74, or regarding potential future revenues from such FAP targeting agents. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the FAP targeting agents, including FAPI-46 and FAPI-74, will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that the FAP targeting agents, including FAPI-46 and FAPI-74, will be commercially successful in the future. In particular, our expectations regarding the FAP targeting agents, including FAPI-46 and FAPI-74,could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About NovartisNovartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com. Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews For Novartis multimedia content, please visit https://www.novartis.com/news/media-library For questions about the site or required registration, please contact media.relations@novartis.com References Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 1999;274(51):36505-12.Loktev A, Lindner T, Burger EM, et al. Development of Fibroblast Activation Protein–TargetedRadiotracers with Improved Tumor Retention. J Nucl Med 2019; 60:1421–1429. doi 10.2967/jnumed.118.224469.Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kindsof Cancer. J Nucl Med 2019; 60:801–805. doi: 10.2967/jnumed.119.227967.Rettig WJ, Garin-Chesa P, Healey JH, et al. Regulation and Heteromeric Structure of the Fibroblast Activation Protein in Normal and Transformed Cells of Mesenchymal and Neuroectodermal Origin. Cancer Res. 1993;53:3327–3335.Lidner T, Loktev A, Altmann A, et al. Development of quinoline based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med 2018 Sep;59(9):1415-1422. doi:10.2967/jnumed.118.210443.Liao L, Ni Y, He R, et al. Clinical implications of fibroblast activation protein-a in non-small cell lung cancer after curative resection:a new predictor for prognosis. J Cancer Res Clin Oncol. 2013;139:1523–1528. doi: 10.1007/s00432-013-1471-8.Saigusa S, Toiyama Y, Tanaka K, et al. Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy. Int J Oncol 2011;38: 655-663. doi: 10.3892/ijo.2011.906. # # # Novartis Media RelationsE-mail: media.relations@novartis.com Anja von TreskowNovartis Strategy & Financial Communications +41 79 392 8697 Anja.von_treskow@novartis.com Julie MasowNovartis US External Engagement+1 862 579 8456Julie.masow@novartis.com Rachel LevineAdvanced Accelerator Applications, a Novartis company Communications+1 917 375 2935 Rachel.levine@novartis.com Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com Central North America Samir Shah+41 61 324 7944Sloan Simpson+1 862 778 5052Thomas Hungerbuehler Isabella Zinck+41 61 324 8425+41 61 324 7188

Let’s block ads! (Why?)



Source link

Continue Reading

Media

Applications open for Pattison Media 2021 Prairie Equity Scholarship – Lethbridge News Now

Published

 on


(Lethbridge News Now)

By Pattison Media

Apr 19, 2021 12:01 PM

LETHBRIDGE, AB – Applications are now being accepted for Pattison Media’s 2021 Prairie Equity Scholarship competition.

The scholarship is aimed at broadcast and digital media students in the Prairie provinces who are part of under-represented groups.

Two awards of $2,000 will be made to residents of Alberta, Saskatchewan, or Manitoba who in 2021 are attending or planning to attend a recognized broadcast or digital media program at a post-secondary institute in one of the three provinces.

Information and application package

Let’s block ads! (Why?)



Source link

Continue Reading

Media

‘Godzilla vs. Kong’ Tops Box Office Again, Crosses $80 Million in the U.S.

Published

 on

OTTAWA (Reuters) – Canada will set aside C$12 billion ($9.6 billion) to extend its main pandemic support measures in a budget to be presented on Monday, the Toronto Star reported, as much of the country battles a virulent third wave of COVID-19 infections.

The emergency wage subsidy and the emergency rent subsidy, due to expire in June, will be extended to the end of September, the Star reported on Sunday.

Separately, the government will create the “Canada Recovery Hiring Program” in June meant to help those companies depending on the wage subsidy to pivot to hiring again, the newspaper said.

The Finance Ministry declined to confirm or comment on the report. However, Environment Minister Jonathan Wilkinson told the Canadian Broadcasting Corp on Sunday that government pandemic supports would continue for as long as needed.

“If Canadians need that support and the pandemic continues, the government will certainly have their backs,” Wilkinson said.

Wilkinson also confirmed that the budget would be “ambitious” and that the government would “invest for jobs and growth to rebuild this economy,” though he also said there would be “fiscal guardrails” to put spending on a “sustainable track”.

Finance Minister Chrystia Freeland will present the country’s first budget in two years on Monday after promising in November up to C$100 billion in stimulus over three years to “jump-start” an economic recovery during what is likely to be an election year.

Canada has been ramping up its vaccination campaign but still has a smaller percentage of its population inoculated than dozens of other countries, including the United States and Britain.

Amid a spiking third wave of infections, Ontario, Canada‘s most populous province, announced new public health restrictions on Friday, including closing the province’s borders to domestic travelers.

($1 = 1.2501 Canadian dollars)

 

(Reporting by Steve Scherer, Editing by Nick Zieminski)

Continue Reading

Media

GLAAD Media Awards presenters support transgender athletes

Published

 on

LOS ANGELES — “Schitt’s Creek” and “The Boys in the Band” were winners at the GLAAD Media Awards, which included soccer’s Ashlyn Harris and Ali Krieger calling for transgender students to be accepted as “part of the team” in sports.

Harris and Krieger, spouses who play for the Orlando Pride and were on the 2019 World Cup-winning U.S. women’s national team, presented an award in Thursday’s virtual ceremony to the film “Happiest Season,” about a lesbian romance.

The couple drew attention to transgender athletes amid widespread efforts to restrict their participation, including a recently signed Mississippi bill that bans them from competing on girls or women’s sports teams. It becomes law July 1.

“Trans students want the opportunity to play sports for the same reason other kids do: to be a part of a team where they feel like they belong,” Krieger said.

Added Harris: “We shouldn’t discriminate against kids and ban them from playing because they’re transgender.”

“Star Trek: Discovery,” “I May Destroy You” and “A Little Late with Lilly Singh” were among the other projects honoured in the pre-taped ceremony hosted by Niecy Nash. It’s available on Hulu through June.

The GLAAD awards, in their 32nd year, recognize what the media advocacy organization calls “fair, accurate, and inclusive” depictions of LGBTQ people and issues. Presenters and winners in this year’s event highlighted priorities including the importance of solidarity and self-respect.

“Friends, I’m so proud to stand with the LGBTQ community tonight, just as the LGBTQ community stands with Black and diverse communities,” said Sterling K. Brown, who presented the outstanding documentary award to “Disclosure.”

The “This Is Us” star, citing the Black Lives Matter and Black Trans Lives Matter movements, said that “we’re going to keep spreading that message of unity and justice until every one of us is safe to live the lives we love.”

JoJo Siwa, the teenage YouTube personality and performer, presented the award for outstanding children’s programming to “The Not-Too-Late Show with Elmo.” She said in January that she’s part of the LGBTQ community.

“I have the best, most amazing, wonderful girlfriend in the entire world who makes me so, so, so happy and that’s all that matters,” Siwa said. ”It’s really cool that kids all around the world who look up to me can now see that loving who you want to love is totally awesome” and should be celebrated.

Other awards went to Sam Smith, who was honoured as outstanding music artist for the album “Love Goes”; Chika, named breakthrough music artist for “Industry Games,” and “We’re Here” won outstanding reality program.

Cast members from “Glee,” including Chris Colfer, Amber Riley and Jane Lynch, paid tribute to Naya Rivera and her character in the series, gay cheerleader Santana Lopez. Rivera, 33, died in an accidental drowning in July 2020.

___

Online:

https://www.glaad.org/

Lynn Elber, The Associated Press







Source:- Coast Reporter

Source link

Continue Reading

Trending